4D Molecular Therapeutics Inc

CEO Kirn David’s 750k stock‑option buy signals strong confidence, yet adds dilution—watch vesting and clinical milestones to gauge impact on the biotech stock.

4D Molecular’s insider option grants signal leadership confidence amid volatile stock, showcasing promising gene‑therapy data and upcoming FDA IND filing.

Insider trades at 4D Molecular Therapeutics reveal a disciplined, rule‑driven pause on new drug delivery, offering investors a chance to gauge future growth amid a strategic pivot.